MMP2 and prostate cancer: The results demonstrated that treatment of the MDA-MB-231 and MDA-MB-468 cells with VNLG-152R at different concentrations for 24 h led to concentration-dependent decreases in the expression of N-Cadherin, β-catenin, MMP-2, MMP-9, Snail, Slug, Vimentin and TCF/ZEB-1 (Figure 6B), consistent with our previous results in PC-3 and CWR22Rv1 prostate cancer cells [33,40].